EUVIMEDEUVIMED entdecken
Open Access

A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry

Oliver Schadt iD, Sebastian Essig, Giambattista Testolin

ChemBioChem · 2026

DOI: 10.1002/cbic.70523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2026. Verfasst von Oliver Schadt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Merck Healthcare KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Drug Industry, Drug Discovery, Small Molecule Libraries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article is an initiative of the Chemical Biology in Industry Working Group of the “European Federation for Medicinal Chemistry and Chemical Biology (EFMC)” connecting discipline experts from several organizations across Europe. In the second half of 2025, we surveyed scientists from the listed organizations to collect precompetitive information on covalent hit identification and validation practices in the pharmaceutical industry. The questionnaire contained 33 questions and covered a broad spectrum of important aspects in covalent drug discovery, including target selection, library characteristics, hit identification, hit validation, and technical limitations. The results are shared and discussed in this article with the goal of generating best practices and providing insights into library design, hit identification, validation, and optimization in covalent drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryDrug DiscoverySmall Molecule LibrariesEuropeHumans

Stichwörter der Autor:innen

EFMCchemical biologychemoproteomicscovalentdrug discoverysurvey

Substanzen

Small Molecule Libraries

Autor:innen und Institutionen

  • Medicinal Chemistry, Merck Healthcare KGaA, Darmstadt, Germany.
  • Zenith Therapeutics AG, Basel, Switzerland.
  • Nuvisan ICB GmbH, Berlin, Germany.

ORCID-Profile: Oliver Schadt

Zitieren

APA

Schadt, O., Essig, S., & Testolin, G. (2026). A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry. ChemBioChem. https://doi.org/10.1002/cbic.70523

Vancouver

Schadt O, Essig S, Testolin G. A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry. ChemBioChem. 2026. doi:10.1002/cbic.70523

BibTeX
@article{Schadt2026,
  author = {Schadt, Oliver and Essig, Sebastian and Testolin, Giambattista},
  title = {A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry},
  journal = {ChemBioChem},
  year = {2026},
  doi = {10.1002/cbic.70523}
}
Kostenlos starten →